[Allevi] Human Hepatocytes

[Allevi] Human Hepatocytes

SKU A-HUCPI

Clinically relevant drug-drug interactions (DDI) are a serious concern for any new drug development project. To better support capturing the multiple mechanisms of DDI potential using primary hepatocytes, we now offer Interaction Qualified Human Hepatocytes (Catalog HUCPI) which are characterized for 3 major mechanisms of DDI: transporter activity, enzyme activity, and induction potential, providing you with one product to meet more of your hepatocyte DDI study needs.

Benefits:

• Use the same donor for basal clearance, transport, and induction studies
• Actual rates of transport reported rather than relative rates for less ambiguity
• Large lots mean fewer rounds of testing so you can focus on results
• Prequalified in Lonza media for better reproducibility

Features:

• Inducibility of enzyme activity for CYP3A4, CYP2B6, and CYP1A2
• Inducibility of mRNA for CYP3A4, CYP2B6, CYP1A2, and CYP2C8 genes
• Actual rate of uptake or efflux for OATP1B1/3, OCT1/2, NTCP, and BSEP** transporters
• Differences in passive vs. active uptake for OATP1B1/3, OCT1/2, and NTCP transporters.
• Basal metabolism for 8 CYPs, SULT, UGT, and aldehyde oxidase
• Plated low-turnover clearance for CYP2C9, CYP2D6, and CYP3A4
• Complementary thawing, plating, and maintenance medium available
• > 5 million viable cells/vial

Applications:

• Drug-Drug interaction studies
• Low clearance metabolism studies
• Drug uptake and efflux
• Disease modeling
• Xenotransplantation
• Short term cellular toxicity studies
• 3D bioprinted models in GelMA, Lifeink® 200, PureCol®, PhotoCol®, PhotoHA®